See the DrugPatentWatch profile for lipitor

Lipitor, a statin medication used to treat high cholesterol, can potentially interact with warfarin, an anticoagulant often prescribed to prevent blood clots. This interaction may affect Warfarin's International Normalized Ratio (INR) range [1].

The INR is a measurement used to monitor the effects of warfarin therapy. A normal INR range is typically between 2.0 and 3.0, but the target range may vary depending on a patient's specific condition [2].

Lipitor, also known as atorvastatin, can impact the metabolism of warfarin in the liver, potentially leading to an increased INR. This increase in INR could enhance the anticoagulant effects of warfarin, increasing the risk of bleeding complications [1].

It is essential to monitor INR closely when initiating, discontinuing, or changing the dose of Lipitor in patients receiving warfarin therapy. Any changes should be made under the guidance of a healthcare professional [1].

In summary, Lipitor can affect Warfarin's INR range by increasing the anticoagulant effects of warfarin, which could lead to an increased risk of bleeding complications.

Sources:
[1] DrugPatentWatch.com. (n.d.). Atorvastatin and Warfarin Drug Interaction. Retrieved from https://www.drugpatentwatch.com/drug-interactions/atorvastatin-and-warfarin
[2] Mayo Clinic. (2021, April 23). International Normalized Ratio (INR). Retrieved from https://www.mayoclinic.org/tests-procedures/international-normalized-ratio/about/pac-20385154